Lytham Partners to Provide Investor Relations
TORONTO, July 2, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated
medical cannabis leader with core operations in Latin America and Europe, announces the results of its 2021
Annual General Meeting of shareholders ("AGM") held on June 30, 2021.
Shareholders approved the resolutions detailed in the management
information circular of the Company dated May 25, 2021, namely:
- Setting the number of directors of the Company at six;
- Electing all six management nominees to the Board of Directors
of the Company, including Juan Carlos
Echeverry, Vicente Fox,
Christopher Naprawa, Deborah Rosati, Alvaro
Torres and Alvaro Yanez;
- Re-appointing BDO Canada LLP as auditors of the Company for the
ensuing year and authorizing the directors to determine the
remuneration of the auditors.
The number of shares represented at the meeting was 52,591,833,
or 34.89% of the issued and outstanding shares of the Company as of
the record date.
Khiron engages Lytham Partners, LLC to provide Investor
The Company is also pleased to announce that it has retained
Lytham Partners, LLC ("Lytham") to provide investor relations
services on a month-to-month basis. Lytham is a leading US-based
investor relations firm with more than two decades of experience
and a specialization in connecting small cap companies with
high-quality and focused institutional investors. The services will
include support for investment community outreach and corporate
communications. As consideration for the services, Lytham will
receive US$6,500 per month. At the
time of this agreement, neither Lytham nor its principals have any
direct or indirect interest in the Company's securities. The
engagement of Lytham remains subject to the approval of the TSX
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis
company with core operations in Latin
America and Europe.
Leveraging wholly-owned medical health centres and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany
and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
SOURCE Khiron Life Sciences Corp.